Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR
return of 21.1% since its launch. Ranked 35 in Sectoral
category. Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% . NAV as on 26 Jul 24 ₹482.709 ↑ 8.99 (1.90 %) Net Assets (AUM) as on 30 Jun 2024 ₹7,404 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio 1.94 Expense Ratio 1.97 % Sharpe Ratio 2.122 Information Ratio -0.14 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 26 Jul 24 Duration Returns 1 Month 6.6% 3 Month 10.9% 6 Month 16.2% 1 Year 42.1% 3 Year 14.8% 5 Year 27.4% 10 Year 15 Year Since launch 21.1% Historical Annual Returns
Year Returns 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% Growth of 10k Over Years
Date Value 30 Jun 19 ₹10,000 30 Jun 20 ₹13,299 30 Jun 21 ₹21,524 30 Jun 22 ₹18,381 30 Jun 23 ₹22,333 30 Jun 24 ₹31,441 Asset Allocation
Asset Class Value Cash 0.56% Equity 99.44% Sector Allocation
Sector Value Health Care 98.35% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 13% ₹997 Cr 6,556,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 8% ₹621 Cr 1,350,808
↑ 100,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPINDrug Manufacturers - Specialty & Generic 8% ₹568 Cr 3,503,676 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLADrug Manufacturers - General 6% ₹459 Cr 3,100,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDYDrug Manufacturers - Specialty & Generic 6% ₹448 Cr 700,030
↑ 150,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSPMedical Care Facilities 5% ₹401 Cr 648,795 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | ZYDUSLIFEDrug Manufacturers - Specialty & Generic 4% ₹290 Cr 2,700,632 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - General 4% ₹274 Cr 1,500,000
↓ -200,000 Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIADrug Manufacturers - General 3% ₹239 Cr 86,390 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350Diagnostics & Research 3% ₹237 Cr 3,161,151
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 19.26 Yr. Kinjal Desai 25 May 18 6.1 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Ltd Address KFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar, FAX 91-40-23311968 Email mailmanager@karvy.com Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹122.899
↑ 2.29 15.32 % 41.05 % 16.11 % 29.97 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹122.899
↑ 2.29 15.32 % 41.05 % 16.11 % 29.97 % Nippon India Pharma Fund
Growth ₹482.709
↑ 8.99 16.18 % 42.1 % 14.75 % 27.37 % Data as on 26 Jul 24